As of Jun 22, 2026, MDT's PEG ratio of 6.41 reflects its valuation relative to its growth rate. This result reflects a P/E ratio of 21.14 measured against EPS growth of 3.3%. When compared to the trailing 4-quarter average of 3.25, MDT's PEG ratio reflects a 97% increase.
Medtronic's ten years historical PEG ratio has a mean of 2.26. Compared to historical data, MDT's 6.41 PEG ratio represents an increase of 184%. MDT hit its maximum PEG ratio of 8.32 during the Jan 2024 quarter over the last ten years. The Jan 2017 quarter marked the lowest reading at 0.27, indicating the most favorable growth-adjusted valuation.
| Year | PEG ratio | PE ratio | Growth YoY |
|---|---|---|---|
| 2026 | 6.73 | 22.22 | 3.3% |
| 2025 | 0.75 | 23.18 | 31% |
| 2024 | N/A | 28.79 | -2.1% |
| 2023 | N/A | 32.14 | -24.5% |
| 2022 | 0.7 | 27.83 | 39.9% |
| 2021 | N/A | 48.85 | -24.9% |
| 2020 | 7.32 | 27.82 | 3.8% |
| 2019 | 0.51 | 25.39 | 50.2% |
| 2018 | N/A | 35.5 | -21.6% |
| 2017 | 1.75 | 28.46 | 16.3% |
| 2016 | 10.87 | 31.53 | 2.9% |
| 2015 | N/A | 31.81 | -20.3% |
| 2014 | N/A | 19.02 | -10% |
| 2013 | N/A | 13.64 | -0.9% |
| 2012 | 0.56 | 10.99 | 19.5% |
| Year | PEG ratio | PE ratio | Growth YoY |
|---|---|---|---|
| Apr 2026 | 6.73 | 22.22 | 3.3% |
| Jan 2026 | 3.18 | 28.02 | 8.8% |
| Oct 2025 | 1.92 | 25.18 | 13.1% |
| Jul 2025 | 1.16 | 25.53 | 22.1% |
| Apr 2025 | 0.75 | 23.18 | 31% |
| Jan 2025 | 5.34 | 27.25 | 5.1% |
| Oct 2024 | 4.05 | 27.53 | 6.8% |
| Jul 2024 | 2.75 | 26.41 | 9.6% |
| Apr 2024 | N/A | 28.79 | -2.1% |
| Jan 2024 | 8.32 | 27.47 | 3.3% |
| Oct 2023 | N/A | 22.54 | -4.6% |
| Jul 2023 | N/A | 32.44 | -29.9% |
| Apr 2023 | N/A | 32.14 | -24.5% |
| Jan 2023 | N/A | 27.08 | -16.4% |
| Oct 2022 | N/A | 26.88 | -7.4% |
Measured against past performance, MDT's PEG ratio sits above the 3, 5 and 10-year averages.
With a PEG of 6.41, MDT stands higher than the Healthcare sector and the industry average.
MDT reports a PEG ratio higher than that of peer stocks SYK and BSX.
| Stock name | PEG ratio | Market cap |
|---|---|---|
| BSX Boston Scientific Corp | 0.25 | $66.14B |
| SYK Stryker Corp | 2.11 | $116.54B |
| MDT Medtronic plc | 6.43 | $101.9B |
| EW Edwards Lifesciences Corp | N/A | $49.16B |
| JNJ Johnson & Johnson | N/A | $564.64B |
| ABT Abbott Laboratories | N/A | $153.87B |
| CNMD CONMED Corp | N/A | $979.75M |
| BAX Baxter International Inc | N/A | $10.07B |
| ACH Accendra Health Inc. | N/A | $245.07M |
| IART Integra Lifesciences Holdings Corp | N/A | $1.35B |
MDT has a PEG ratio of 6.41, per Jun 22, 2026 data.
MDT has a 3-year average PEG ratio of 3.8.
MDT has a 5-year average PEG ratio of 2.85.
The Jan 2024 quarter marked the ten years high at 8.32 for MDT's PEG ratio.
At present, MDT's PEG ratio is 184% higher than its 10-year historical average.
The elevated PEG ratio of 6.41 indicates that MDT may be priced above its earnings growth potential.
To calculate the PEG ratio, take the company's PE ratio and divide by its earnings per share growth (YoY TTM). As of Jun 22, 2026, Medtronic has a PE ratio of 21.14. Earnings grew at 3.3% over the TTM period ending Apr 2026. Applying the formula, this gives a PEG ratio of 6.41. PEG RATIO(6.41) = PE RATIO(21.14) / EPS GROWTH(3.3%)
All PEG ratio stats are based on quarterly TTM periods, unless otherwise specified.